Tumor senescence and radioresistant tumor-initiating cells (TICs): Let sleeping dogs lie!

Breast Cancer Research

Volumn 12, Issue 4, 2010, Pages

  Zafarana, Gaetano ^a   Bristow, Robert G ^a,b  

^a Departments of Radiation Oncology and Medical Biophysics   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CHECKPOINT KINASE 2; HERMES ANTIGEN; HISTONE H2AX; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; DNA; GAMMA HISTONE H2AX; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; H2AFX PROTEIN, HUMAN; HISTONE; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; CELL AGING; CELL SURVIVAL; CLONOGENESIS; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EDITORIAL; GENE ACTIVATION; IN VIVO STUDY; IONIZING RADIATION; METASTASIS; NONHUMAN; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR RECURRENCE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER REGRESSION; CANCER RESISTANCE; CANCER STEM CELL; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; OXIDATIVE STRESS; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SINGLE STRANDED DNA BREAK; TUMOR SENESCENCE; WNT SIGNALING PATHWAY; BIOLOGICAL MODEL; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; NOTE; PATHOLOGY; RADIATION EXPOSURE;

ANTIGENS, CD24; ANTIGENS, CD44; APOPTOSIS; BREAST NEOPLASMS; CELL AGING; DNA DAMAGE; DNA REPAIR; FEMALE; HISTONES; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650914775     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2597     Document Type: Editorial

References (21)

1. Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010, 12:R31. 10.1186/bcr2583, 20525204.
2. Bartelink H. Progress in radiotherapy for early breast cancer. Ann Oncol 2008, 19(Suppl 5):v117-121. 10.1093/annonc/mdn324, 18611868.
3. Moran MS, Haffty BG. Radiation techniques and toxicities for locally advanced breast cancer. Semin Radiat Oncol 2009, 19:244-255. 10.1016/j.semradonc.2009.05.007, 19732689.
4. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785. 10.1093/jnci/djj495, 17179479.
5. Woodward WA, Bristow RG. Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol 2009, 19:87-95. 10.1016/j.semradonc.2008.11.003, 2700289, 19249646.
6. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci USA 2010, 107:3522-3527. 10.1073/pnas.0910179107, 20133717.
7. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783. 10.1038/nature07733, 2778612, 19194462.
8. Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. Int J Radiat Oncol Biol Phys 2009, 74:1580-1591.
9. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010,
10. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760. 10.1038/nature05236, 17051156.
11. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009, 15:5145-5153. 10.1158/1078-0432.CCR-09-0263, 19671863.
12. Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res 2010, 12:R13. 10.1186/bcr2479, 2880434, 20158881.
13. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010, 10:51-57. 10.1038/nrc2772, 20029423.
14. Koch U, Krause M, Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures-Radiation oncology perspective. Semin Cancer Biol 2010, 20:116-124. 10.1016/j.semcancer.2010.02.003, 20219680.
15. Hill RP, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989, 16:513-518.
16. Bristow RG Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192. 10.1038/nrc2344, 18273037.
17. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009, 19:106-111. 10.1016/j.semradonc.2008.12.002, 19249648.
18. Bristow RG, Peacock J, Jang A, Kim J, Hill RP, Benchimol S. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53. Oncogene 2003, 22:2960-2966. 10.1038/sj.onc.1206405, 12771947.
19. Suit H, Allam A, Allalunis-Turner J, Brock W, Girinsky T, Hill S, Hunter N, Milas L, Pearcey R, Peters L, Welch DR, West CM, Efird J. Is tumor cell radiation resistance correlated with metastatic ability?. Cancer Res 1994, 54:1736-1741.
20. Hamburg M, Collins F. The path to personalized medicine. N Engl J Med 2010,
21. Roy R, Willan P, Clarke R, Farnie G. Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy. Breast Cancer Res 2010, 12(Suppl 1):O5. 10.1186/bcr2496, 2875561, 20497593.